SLC2A5 and diabetes mellitus: MSNBA together with the active site differences between GLUT5 and GLUT1 highlighted by MSNBA inhibition can be exploited for the rational design of potent, specific inhibitors for GLUT5 that will aid in cancer or diabetes treatment.